A Phase I Trial of HS-10241 in Solid Tumors
First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors
調査の概要
詳細な説明
Recently, c-Met has become an important target of intensive research in search of specific inhibitors as potential new therapies for cancers driven by c-Met activation. HS-10241 is a potent and selective small molecule c-Met kinase inhibitor for both enzyme and c-Met phosphorylation in the cell. Consistent with its potent enzyme and cell activity, HS-10241 was found to inhibit cell growth in vitro against tumors with c-Met gene amplification or c-Met overexpression. On the basis of these findings, the current trial will be conducted in participants with advanced solid tumors for whom standard treatment is not currently available.
This study consists of 2 phases. In the dose-escalation phase, up to 5 dose levels of HS-10241 (100 mg/day, 200 mg/day, 340 mg/day, 500 mg/day, and 700 mg/day) will be investigated with a sequential "3+3" design (3 or 6 participants in every dose level). Participants will have a single-dose pharmacokinetic (PK) run-in period (7 days). Following the first dose, participants will enter a 1 week treatment-free period to evaluate safety and single-dose PK. If no dose-limiting toxicities (DLTs) are observed during the 1-week period, HS-10241 administration will resume at the same dose level.
In the expansion phase, up to 12 additional participants will be enrolled at the MTD. Anti-tumor effects will be assessed every 2 cycles (4 weeks=1 cycle) by using RECIST version 1.1 criteria.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア、2050
- Chris O'Brien Lifehouse
-
Liverpool、New South Wales、オーストラリア、2170
- Liverpool
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- At least 18 years of age
- Ability to understand the purposes and risks of the trial and his/her informed consent using the Human Research Ethics Committee (HREC) approved informed consent form (ICF).
- Histologically or cytologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed, or has been refused.
- Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 3 months
Acceptable liver function defined below:
- Total bilirubin ≤ 2 times upper limit of normal range (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times ULN; however, ≤5 times ULN in a subject who has liver metastases
Acceptable renal function defined below:
- Serum creatinine ≤1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥60 mL/minutes
Acceptable coagulation status defined below:
- Prothrombin time <1.5 times ULN
- Partial thrombin time <1.5 times ULN
Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:
- Absolute neutrophil count (ANC) ≥1500/μL
- Platelet count ≥100000/μL
- Hemoglobin ≥9.0 g/dL
- No clinically significant abnormalities in urinalysis
- All participants must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an intrauterine device) with their partner from entry into the trial through 6 months after the last dose.
Exclusion Criteria:
- Hematologic malignancies
- Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
- Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris
- Seizure disorders requiring anticonvulsant therapy
- Taking a medication that prolongs QT interval and has a risk of Torsade de Pointes, or a history of long QT syndrome
- Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
- Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry. Ongoing androgen deprivation therapy or bisphosphonates are allowed.
- Participation in an investigational drug or device trial within 4 weeks prior to the trial entry
- Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of trial entry)
- History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis;
- Subject is pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment
- Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial
- History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation
- Unwillingness or inability to comply with the trial protocol for any reason
- Legal incapacity or limited legal capacity
- Known drug abuse or alcohol abuse
- Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9. Patients are eligible if these medications can be stopped or substituted within the screening period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:HS-10241
HS-10241 is administered orally starting at 100 mg/day.
|
HS-10241 is administered orally starting at 100 mg/day.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Maximum tolerated dose (MTD)
時間枠:4 weeks
|
MTD is defined as the maximum dose level at which no more than 1 out of 3 participants experience a DLT within the first 4 weeks of multiple dosing.
|
4 weeks
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
客観的奏効率 (ORR)
時間枠:24ヶ月
|
24ヶ月
|
クリアランス (CL)
時間枠:4週間
|
4週間
|
Peak plasma concentration (Cmax)
時間枠:4 weeks
|
4 weeks
|
T1/2 (half-life)
時間枠:4 weeks
|
4 weeks
|
Volume of distribution at steady state (Vss)
時間枠:4 weeks
|
4 weeks
|
Number of participants with treatment-emergent adverse events (TEAEs)
時間枠:24 months
|
24 months
|
Area under the plasma concentration-time curve (AUC)
時間枠:4 weeks
|
4 weeks
|
Time to reach maximum plasma concentration (Tmax)
時間枠:4 weeks
|
4 weeks
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
固形腫瘍の臨床試験
-
AstraZeneca募集Adv Solid Malig - H&N SCC、ATM Pro / Def NSCLC、胃がん、乳がん、卵巣がんスペイン, アメリカ, ベルギー, イギリス, フランス, ハンガリー, カナダ, 大韓民国, オーストラリア
HS-10241の臨床試験
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.わからない
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.募集
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.わからない